Home > Journals > Minerva Pediatrics > Past Issues > Articles online first > Minerva Pediatrics 2021 May 31

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Pediatrics 2021 May 31

DOI: 10.23736/S2724-5276.21.06287-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Extended-hearing targeted screening for congenital cytomegalovirus infection

Francesca FORLI 1 , Francesco LAZZERINI 1, Rachele CANELLI 1, Francesca LORENZONI 2, Beatrice FRANCIOSI 1, Stefano BERRETTINI 1, 3, Luca BRUSCHINI 1

1 Otolaryngology, Audiology and Phoniatrics Unit, University of Pisa, Pisa, Italy; 2 Division of Neonatology and Neonatal Intensive Care Unit, University of Pisa, Pisa, Italy; 3 Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden


PDF


BACKGROUND: The importance of neonatal screening for congenital cytomegalovirus infection (cCMV) is widely shared in the world scientific literature. However, currently, no programs for universal neonatal screening for cCMV have been reported in the literature, and only a few experiences of hearing targeted cCMV screening have been published. In the Tuscany Region, Italy, screening for cCMV has been mandatory since 2008 for each newborn that result “refer” at the Transient Evoked Otoacoustics Emissions (TEOAE) test, and in our university hospital since 2012, it has been extended to some categories at risk of cCMV.
METHODS: We present the results of the protocol for cCMV screening adopted at our Institution since 2012.
RESULTS: From 2012 to 2017, 1615 newborns underwent cCMV screening. Twenty-five cases were positive for cCMV, (1.54% of all the newborn screened for cCMV and 0.19% of infants submitted to newborn hearing screening). Nineteen of these children (76%) had normal hearing, while 6 (24%) had a hearing deficit of variable degree. 2/25 (8%) cases presented a progression of the hearing deficit in the first months of life and no children had a late onset or fluctuating hearing loss.
CONCLUSIONS: Our findings show how cCMV screening in newborns that result refer at TEOAE allows the detection of many cases; but many are still missed. It would be, therefore, important to adopt a universal newborn cCMV screening program or a program extended to newborns at higher risk.


KEY WORDS: Cytomegalovirus; Hearing loss; Congenital cytomegalovirus; Newborn; Hearing screening

top of page